신경 세포 아포토시스 억제 효과를 갖는 단삼 및 천궁추출 조성물
    1.
    发明公开
    신경 세포 아포토시스 억제 효과를 갖는 단삼 및 천궁추출 조성물 无效
    RADIX SALVIAE MILTIORRHIZAE和RHIZOMA CNIDII的提取抑制人脑神经细胞死亡

    公开(公告)号:KR1020040000615A

    公开(公告)日:2004-01-07

    申请号:KR1020020035115

    申请日:2002-06-22

    Applicant: 박래길

    Abstract: PURPOSE: Provided is a mixed extract of Radix Salviae miltiorrhizae and Rhizoma Cnidii which has inhibition effect on apoptotic neural cell death. Therefore, the extract is clinically useful. CONSTITUTION: A mixed extract of Radix Salviae miltiorrhizae and Rhizoma Cnidii characteristically inhibits apoptotic neural cell death by increasing the cell viability, reducing the condensation and fraction of chromosome, and decreasing the activity of Caspase-3 and the quantity of glutathione in the cell.

    Abstract translation: 目的:提供丹参和枸杞的混合提取物,对凋亡性神经细胞死亡具有抑制作用。 因此,提取物在临床上是有用的。 构成:丹参和枸杞子的混合提取物通过增加细胞活力,降低染色体的缩合和分数,降低细胞中胱天蛋白酶-3的活性和谷胱甘肽的含量,特征性地抑制凋亡性神经细胞死亡。

    항암제와 병용투여시 상승적인 아포토시스 유도효과를갖는 인삼, 복령, 생지황, 초별갑, 천산갑, 백출, 당귀,적작약, 삼능, 봉출, 향부자, 유향, 천궁 및 감초혼합추출물
    2.
    发明公开
    항암제와 병용투여시 상승적인 아포토시스 유도효과를갖는 인삼, 복령, 생지황, 초별갑, 천산갑, 백출, 당귀,적작약, 삼능, 봉출, 향부자, 유향, 천궁 및 감초혼합추출물 无效
    人参,POLIA,RHIZOMA生地黄,AMYDAE CARAPAX,MANITIS鳞片,白术RHIZOMA ALBA,当归GIGANTIS麦冬,赤芍基数杨梅,SCIRPI川芎,莪术川芎,香附川芎,MASTRIX,川芎和甘草提取物基数HAVING协同诱导细胞凋亡的影响 何时与ANTICANCER AGENT一起管理

    公开(公告)号:KR1020030085983A

    公开(公告)日:2003-11-07

    申请号:KR1020020024308

    申请日:2002-05-03

    Applicant: 박래길

    Abstract: PURPOSE: A mixed herbal extract having a synergistic apoptosis-inducing effect when administered together with doxorubicin is provided. The extract increases expression of Fas/Fas-L systems, activates caspase-3, fragments PARP, increases expression of Bax, inhibits activity of gene transcription factor AP-1 and NF-kB and activates JNK in Fas receptor expressing cancer cells to induce apoptosis. CONSTITUTION: A mixed herbal extract of 12g of Ginseng Radix, 12g of Polia, 12g of Rhizoma rehmanniae, 12g of Amydae Carapax, 12g of Manitis Squama, 10g of Atractylodis Rhizoma Alba, 10g of Angelicae Gigantis Radix, 10g of Paeoniae Radix rubra, 10g of Scirpi Rhizoma, Zedoariae Rhizoma, 10g of Cyperi Rhizoma, Mastrix, 9g of Cnidii Rhizoma and 6g of Glycyrrhizae Radix has a synergistic apoptosis-inducing effect when administered together with an anticancer agent in Fas expressing cancer cell. The cancer cells are selected from the group consisting of Chang cell lines and HL-60 cell lines.

    Abstract translation: 目的:提供与多柔比星一起施用时具有协同凋亡诱导作用的混合草药提取物。 提取物增加Fas / Fas-L系统的表达,激活caspase-3,片段PARP,增加Bax的表达,抑制基因转录因子AP-1和NF-kB的活性,并激活Fas受体表达的癌细胞中的JNK诱导细胞凋亡 。 构成:将12g人参,混合12g的Polia,12g的地黄,12g的Amydae Carapax,12g的Manitis Squama,10g的Atractylodis Rhizoma Alba,10g的当归,10g的芍药,10g 的镰刀菌属,禾本科,10g的Cyperi Rhizoma,Mastrix,9g Cnidii Rhizoma和6g甘草,当与Fas表达的癌细胞中的抗癌剂一起施用时,具有协同的细胞凋亡诱导作用。 癌细胞选自Chang细胞系和HL-60细胞系。

    심근 세포 아포토시스 억제 효과를 갖는 단삼 및 천궁추출 조성물
    3.
    发明公开
    심근 세포 아포토시스 억제 효과를 갖는 단삼 및 천궁추출 조성물 无效
    RADIX SALVIAE MILTIORRHIZAE和RHIZOMA CNIDII抑制APOPTOTIC CARDIAC细胞死亡的提取

    公开(公告)号:KR1020040000651A

    公开(公告)日:2004-01-07

    申请号:KR1020020035166

    申请日:2002-06-22

    Applicant: 박래길

    Abstract: PURPOSE: Provided is a mixed extract of Radix Salviae miltiorrhizae and Rhizoma Cnidii which has inhibition effect on apoptotic cardiac cell death. Therefore, the extract is clinically useful. CONSTITUTION: A mixed extract of Radix Salviae miltiorrhizae and Rhizoma Cnidii characteristically inhibits apoptotic cardiac cell death by increasing the cell viability, reducing the fraction of DNA and PARP, decreasing the activity of Caspase-3 protease and caspase-9 protease and inhibiting the damage to mitochondrial membrane potential, as well as mitochondrial cytochrome c. The extract synergistically inhibits apoptotic cardiac cell death by combined administration with the antioxidant, N-acetylcysteine(NAC).

    Abstract translation: 目的:提供丹参和苦参碱的混合提取物,对凋亡性心脏细胞死亡具有抑制作用。 因此,提取物在临床上是有用的。 构成:丹参和枸杞子的混合提取物通过增加细胞活力,降低DNA和PARP的分数,降低Caspase-3蛋白酶和半胱天冬酶-9蛋白酶的活性,抑制细胞凋亡,抑制凋亡的心脏细胞死亡 线粒体膜电位,以及线粒体细胞色素c。 提取物通过与抗氧化剂N-乙酰半胱氨酸(NAC)的联合给药协同抑制凋亡性心脏细胞死亡。

Patent Agency Ranking